Recall of m24sp Instrument System (sample extraction system). An in vitro diagnostic medical device (IVD)

According to Department of Health, Therapeutic Goods Administration, this recall involved a device in Australia that was produced by Abbott Australasia Pty Ltd Molecular Division.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
  • Event ID
  • Event Risk Class
    Class II
  • Event Initiated Date
  • Event Country
  • Event Source
  • Event Source URL
  • Notes / Alerts
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Extra notes in the data
  • Reason
    Abbott molecular has identified that when duplicate sample ids are used for multiple replicates of a sample, calibrator or control in the same run: some samples may not be included in the plate report; some duplicate sample ids are reassigned a unique identifier by the software and a warning message is displayed in the plate report. these issues occur if duplicate sample ids are used within a run, on the m24sp plate report. the m24sp plate report is a pdf file generated by the software for each instrument run. it provides a list of sample id’s and their processing information and error status.
  • Action
    Abbott Molecular is advising users that to ensure proper function of the Plate Report, duplicate sample IDs should not be used on the m24sp. If two or more replicates of a sample, calibrator or control are being run, a unique sample ID should be used for each of the replicates. This action has been closed-out on 15/07/2016.



  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source